"10.1371_journal.pone.0148747","plos one","2016-02-11T00:00:00Z","William B Stubblefield; Nathan J Alves; Matthew T Rondina; Jeffrey A Kline","Louisiana State University, Health Sciences Center, New Orleans, United States of America; Indiana University School of Medicine, Indianapolis, United States of America; University of Utah School of Medicine, Salt Lake City, United States of America; Department of Emergency Medicine, and Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, IN, United States of America","Conceived and designed the experiments: WBS NJA JAK. Performed the experiments: WBS. Analyzed the data: WBS NJA JAK MTR. Contributed reagents/materials/analysis tools: JAK MTR. Wrote the paper: WBS NJA JAK MTR.","Jeffrey A. Kline has honoraria from Stago, Janssen, and other academic institutions; grants pending with NIH, AHRQ, and Ikaria; and is inventor on a pending US patent “Tunable delivery of a nanoparticle bound active plasmin for the treatment of thrombosis”. No board membership, consultancy or employment related to the submitted work. William B. Stubblefield, Nathan J. Alves, and Matthew T. Rondina have declared that no competing interests exist. Tissue plasminogen activator was in-kind gift of Genentech. The original clinical trial was investigator-initiated, funded by Genentech. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2016","02","William B Stubblefield","WBS",4,FALSE,3,1,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
